Blog

Advanced Medical Solutions (LSE:AMS) reported record financial results for 2025, with group revenue rising 29% to £228.9 million and adjusted EBITDA increasing 24% to £49.9 million. The performance was supported by strong organic growth alongside the first full-year contribution from the Peters Surgical acquisition.

The Surgical division delivered particularly strong momentum, with sales climbing 36% at constant currency to £183.5 million. Growth was driven by double-digit increases across key product categories including LiquiBand surgical adhesives, biosurgical devices and suture-related products. Meanwhile, the Advanced Woundcare segment recorded 9% growth as restructuring measures began to improve performance.

Management highlighted the successful integration of both the Peters Surgical and Syntacoll acquisitions. Early commercial synergies have already contributed to increased sales, while additional operational synergies are expected to be realised from 2027. The company also pointed to a strong innovation pipeline covering surgical adhesives, sutures, collagen technologies and bone substitute products.

Despite continued investment in manufacturing transformation initiatives, net debt declined to £50.5 million. Reflecting confidence in the group’s financial position, the board proposed a 10% increase in the dividend. Looking ahead, management expects both revenue and EBITDA in 2026 to meet current market forecasts, supported by sustained strength in the Surgical division and more modest growth in Advanced Woundcare.

Advanced Medical Solutions’ outlook reflects a combination of strong revenue growth and a solid balance sheet, although some pressure on profitability margins remains a challenge. Technical indicators suggest a generally positive share price trend, but valuation metrics imply the stock may already reflect much of the growth potential. Recent corporate developments, including strategic acquisitions and continued engagement with investors, underline the company’s long-term expansion strategy.

More about Advanced Medical Solutions

Advanced Medical Solutions Group is a UK-based medical technology company specialising in tissue-healing solutions for surgical and advanced wound care applications. Its product portfolio includes skin adhesives and sealants, biosurgical devices, sutures, clips and collagen-based materials. The company serves healthcare markets worldwide through a combination of direct sales channels and strategic partnerships, with a growing global footprint in surgical and woundcare technologies.

Diploma (LSE:DPLM) has upgraded its guidance for the 2026 financial year following strong trading performance. The company now expects organic revenue growth of about 9%, up from its previous forecast of 6%, and has increased its operating margin target to roughly 25%.

The revised outlook implies an estimated 13% increase in consensus operating profit forecasts and points to earnings growth of more than 20% for the year. Management cited continued momentum in the first half of the financial year and growing confidence in second-half performance as key drivers behind the improved expectations.

Performance has been broad-based across Diploma’s portfolio. Aerospace-focused Peerless delivered particularly strong growth, while IS Group, Clarendon and Windy City Wire also reported solid progress. The life sciences segment remained resilient, helping to offset softer market conditions within the International Seals business.

Margin expansion has been supported by the accretive contribution from Peerless and other operating units. The company has also continued to pursue its acquisition-led growth strategy, completing deals worth approximately £130 million and maintaining a strong pipeline of potential opportunities. This ongoing buy-and-build approach remains central to Diploma’s strategy as it aims to sustain high returns and long-term earnings growth.

Diploma’s outlook is primarily supported by strong financial performance, including robust revenue growth and solid cash generation. However, technical indicators currently point to bearish momentum in the share price, and valuation metrics suggest the stock may be relatively expensive, potentially limiting near-term upside. In addition, the absence of recent earnings call commentary or major corporate developments leaves less visibility into additional catalysts.

More about Diploma

Diploma is a FTSE 100 value-added distribution and services group supplying specialised products across the controls, seals and life sciences sectors. The company operates mainly in the United States, Canada, the United Kingdom, Europe and Australia, employing around 3,400 people. Over the past seven years, Diploma has delivered average adjusted earnings-per-share growth of roughly 18% annually, driven by a combination of organic expansion and targeted acquisitions.

Goldplat (LSE:GDP) delivered a strong performance for the six months to 31 December 2025, with revenue increasing 53% to £45.2 million and operating profit reaching £4.8 million. The results were driven largely by higher gold production from the company’s South African operations and a stronger average gold price during the period.

Net profit attributable to shareholders rose 133% to £3.3 million, while fully diluted earnings per share more than doubled to 1.91 pence. Although cash balances declined following the settlement of significant payables and continued investment in capital expenditure and dividends, the group maintained a solid net cash position.

During the period, Goldplat also initiated a regular dividend programme. The company paid £350,000 in dividends during the half-year and £600,000 over the past eight months, reflecting management’s confidence in ongoing cash generation. At the same time, the group continued investing in operational improvements at its Ghanaian operations and in the development of a new processing facility in Brazil.

Looking ahead, management aims to maintain and expand its market share in South Africa while improving recovery rates and profitability in Ghana, where beneficiation requirements influence operations. The company is also working to grow sourcing and service capabilities in South America. In addition, Goldplat is advancing plans to collaborate with DRDGOLD on the reprocessing of a tailings storage facility, which could further strengthen its position in the niche precious metals recovery market.

Goldplat’s outlook is supported by its strong balance sheet and solid cash flow generation. However, these positives are partly offset by signs of declining revenue momentum and some pressure on profit margins. From a technical perspective, the share price trend remains positive but appears somewhat stretched, with elevated RSI and stochastic indicators. Valuation metrics currently suggest a fair rather than deeply discounted level following the recent operational developments.

More about Goldplat

Goldplat plc is an AIM-listed mining services company specialising in precious metals recovery. The group operates primary gold recovery facilities in South Africa and Ghana and is expanding sourcing activities in South America, including Brazil. Goldplat focuses on processing mining by-products and low-grade materials, providing specialised recovery solutions for gold and other precious metals across the African and South American mining sectors.

Genel Energy (LSE:GENL) reported average working interest production of 17,520 barrels of oil per day from the Tawke field in 2025. All output was sold within the domestic Kurdistan market at an average realised price of $32 per barrel, generating $68.7 million in revenue and delivering EBITDAX of $43.3 million despite weaker Brent crude prices.

The company finished the year with $224 million in cash and $133.7 million in net cash. During the period, Genel refinanced its outstanding bond to extend its maturity to 2030, improved operating netback to $10 million, and exited five underperforming licences in Kurdistan and Africa without leaving residual liabilities.

Management highlighted the development of a more resilient and cash-generative operating platform. Free cash flow remained positive at $4.1 million, while overdue receivables from the Kurdistan Regional Government were reduced to approximately $48 million after accounting for offsets and credits. A $26 million charge related to an arbitration case remains under appeal.

Operationally, the company faced disruption during the year, including temporary production halts at Tawke following regional hostilities and drone attacks. In addition, exports through the Iraq–Türkiye pipeline have yet to resume for the company. Despite these challenges, Genel expects domestic sales from Tawke and additional drilling activity to cover group operating costs in 2026.

Looking ahead, the company plans to invest up to $20 million in exploration projects in Oman and Somaliland while continuing to pursue potential asset acquisitions. Management also highlighted the potential for improved shareholder returns if export routes reopen and operating conditions stabilise.

Genel Energy’s outlook reflects a mixed financial profile. While revenue pressures persist, the company continues to generate operating cash flow and has improved its free cash flow position alongside manageable debt levels. Technical indicators appear largely neutral, with a slightly negative MACD trend. Valuation metrics remain constrained by a negative price-to-earnings ratio and the absence of a dividend yield.

More about Genel Energy

Genel Energy is an independent oil and gas exploration and production company focused primarily on the Kurdistan Region of Iraq, alongside exploration interests in frontier basins including Oman and Somaliland. Its core operations centre on crude production from the Tawke field, while the company continues to pursue exploration opportunities aimed at expanding reserves, resources and future cash flow potential.

EnSilica (LSE:ENSI) has conditionally raised approximately £10 million through a combination of a placing, subscription and an oversubscribed retail offer priced at 47 pence per share. The fundraising attracted strong interest from institutional investors as well as existing retail shareholders.

Demand for the retail portion alone exceeded £0.9 million, although allocations were limited to around £0.3 million. The company applied a soft pre-emption approach to prioritise participation by existing shareholders.

The first tranche of the fundraising, amounting to about £4.54 million, has already been completed. The remaining proceeds—including the retail offer and a second tranche placing—are subject to shareholder approval at a general meeting scheduled for 7 April 2026. If approved, 11,616,531 new shares are expected to be admitted to trading on AIM on 8 April 2026, providing the company with additional capital to advance its growth plans and strengthen its position in specialist semiconductor markets.

Despite the successful fundraising, EnSilica’s outlook remains affected by financial challenges. The company has reported declining revenue, continued losses and a significant deterioration in free cash flow, although its balance sheet leverage remains relatively manageable. Market technical indicators provide some support, with the share price trading well above major moving averages and showing strong upward momentum, though these indicators suggest the stock may be approaching stretched levels. Valuation is also constrained by the company’s negative price-to-earnings ratio and the absence of a dividend yield.

More about EnSilica plc

EnSilica is a UK-based fabless semiconductor company focused on the design and development of application-specific integrated circuits (ASICs). The company specialises in RF, millimetre-wave, mixed-signal and complex digital chip design for industries including space and communications, industrial systems, automotive and healthcare. By leveraging reusable intellectual property and silicon platforms, EnSilica aims to deliver scalable and production-ready semiconductor solutions with an emphasis on safety, security and reliability.

FDM Group (LSE:FDM) reported significantly lower financial results for 2025 as challenging market conditions and extended client decision timelines reduced demand for its consulting services. Revenue fell 31% to £177.7 million, while profit before tax dropped 73% to £7.6 million.

The number of consultants deployed to clients declined 22% to 2,003 during the year, though utilisation rates remained broadly stable. In response to the slowdown, the company reduced recruitment activity and implemented cost measures, including £2.6 million in exceptional restructuring charges and a £3.3 million impairment related to its EMEA operations.

Despite the weaker earnings performance, FDM maintained a robust financial position with a debt-free balance sheet and £35.3 million in cash at year-end. The company also reported strong cash conversion and proposed a reduced total dividend of 10 pence per share.

Management noted increasing interest from clients in consultants with artificial intelligence capabilities. To capture this opportunity, the company has introduced a sales transformation programme and is adjusting internal staffing and resource allocation across regions to better align with evolving client demand. These initiatives are intended to position the business for a return to sustainable growth once macroeconomic and geopolitical conditions stabilise.

FDM’s outlook is supported by its solid financial fundamentals and relatively attractive valuation metrics. Healthy margins, low leverage, a strong dividend yield and a low price-to-earnings ratio contribute positively to the investment case. However, technical indicators suggest caution due to overbought trading conditions, while the absence of recent earnings call commentary limits visibility on near-term guidance.

More about FDM Group (Holdings) plc

FDM Group (Holdings) plc is a global professional services firm specialising in information technology and tech-enabled business talent solutions. The company provides AI-enabled and early-career technology consultants to organisations across multiple industries and regions. Its services focus on supporting digital transformation initiatives, including data management, automation, governance and advanced technology capabilities.

Gore Street Energy Storage Fund (LSE:GSF) reported an unaudited net asset value of 87.9 pence per share as of 31 December 2025, compared with 90.1 pence previously. When adjusting for the impact of a special dividend, the company said underlying NAV remained broadly stable over the period.

Quarterly revenue increased 24% to £9.7 million, supported by additional operational capacity in the United States. However, revenue generated per megawatt declined due to changes in market conditions and a shift in the composition of the asset portfolio.

The fund reaffirmed its updated strategic direction by declaring a quarterly dividend of 1.75 pence per share, maintaining its annual dividend target of 7.0 pence per share. Management also confirmed that an additional special dividend remains under consideration, pending final approvals linked to the monetisation of U.S. tax credits.

Operationally, the company made progress across several initiatives aimed at strengthening cash generation and improving efficiency. These include duration upgrades at the Stony and Ferrymuir battery storage assets, selective asset disposals, further deployment of the GSET trading platform, and the development of a new data platform. Together, these measures are intended to enhance operational performance, reduce costs and strengthen the fund’s competitive positioning in the increasingly crowded energy storage market.

From a financial perspective, the company’s outlook benefits from a strong solvency position and solid recent cash generation. Shareholder-focused actions such as cost control measures, strategic investments and director share purchases provide additional support. However, these positives are partly offset by weak technical indicators, including a downward share price trend and negative momentum. Operating results have also been volatile, and while the fund offers a high dividend yield, valuation metrics remain pressured by a negative price-to-earnings ratio.

More about Gore Street Energy Storage

Gore Street Energy Storage Fund is a London-listed investment company specialising in grid-scale battery energy storage systems across Great Britain, Ireland, Germany and the United States. The fund generates revenue through a mix of ancillary grid services, power trading and contracted capacity arrangements. Its strategy focuses on delivering stable income and capital growth by capitalising on opportunities created by the energy transition and volatility in electricity markets.

Great Western Mining (LSE:GWMO) has increased the size of its Defender-Pine Crow Tungsten Project in Nevada by staking eight additional claim blocks covering 165.3 acres. The newly acquired ground extends the company’s holdings to the north and east within the Black Mountains, strengthening its control over an area that has already demonstrated high-grade tungsten potential.

The expanded claims create a larger operational buffer around known mineral occurrences that form the core of the company’s exploration focus. By consolidating its land position, Great Western Mining aims to enhance exploration flexibility and support future resource definition at the project.

Management said the enlarged land package forms an important part of its 2026 development strategy, which targets delivery of an initial Mineral Resource Estimate for Defender-Pine Crow before the end of the year. With winter conditions easing and exploration activities fully funded, the company expects fieldwork to restart within the coming weeks. The upcoming campaign is intended to build momentum and generate a consistent flow of exploration updates throughout the field season.

Despite these operational plans, the company’s broader outlook remains constrained by financial challenges. Great Western Mining continues to operate without revenue while reporting recurring losses and ongoing cash burn, although leverage remains low. Technical indicators are relatively supportive, with the share price trading above major moving averages and showing moderately positive momentum. However, valuation metrics remain limited by the company’s negative price-to-earnings ratio and the absence of dividend yield data.

More about Great Western Mining

Great Western Mining Corporation is an exploration and development company listed on AIM and Euronext Growth. The firm focuses on strategic minerals across its wholly owned claim groups in Mineral County, Nevada—one of the most mining-friendly jurisdictions globally. Its portfolio includes projects targeting copper, gold, silver and tungsten, notably the Huntoon Copper Project, which hosts a JORC-compliant resource and aligns with U.S. priorities around securing critical mineral supply.

Oxford Biomedica (LSE:OXB) has entered a five-year licensing and option agreement with Viral Vector Manufacturing Facility (VVMF), Australia’s first dedicated commercial viral vector contract development and manufacturing organisation. The deal grants VVMF a worldwide, non-exclusive licence to Oxford Biomedica’s inAAVate platform, along with an option to access its LentiVector technology.

Under the terms of the agreement, Oxford Biomedica will receive an upfront payment in the low single-digit millions, with the potential for additional payments in the future. VVMF intends to use the licensed technologies to accelerate the development of its viral vector manufacturing capabilities and support the build-out of advanced production infrastructure.

The collaboration is expected to strengthen Australia’s position as a hub for cell and gene therapy manufacturing within the Asia-Pacific region while expanding Oxford Biomedica’s global presence. The agreement also reinforces the company’s role as a provider of scalable viral vector technologies used by pharmaceutical and biotechnology partners worldwide.

Despite strong recent revenue growth, Oxford Biomedica’s broader outlook remains constrained by financial challenges, including continued losses, negative cash flow and relatively high leverage. Market technical indicators currently appear supportive, with the shares trading in a clear uptrend and showing positive MACD momentum. However, very elevated RSI and stochastic readings suggest the stock may be overbought in the near term. Valuation metrics also remain limited due to negative earnings and the absence of a dividend yield.

More about Oxford Biomedica

Oxford Biomedica is a UK-headquartered contract development and manufacturing organisation specialising in cell and gene therapy. With roughly three decades of experience in viral vector technology, the company provides end-to-end development and manufacturing services for lentiviral, adeno-associated and other viral vectors. Its clients include global pharmaceutical and biotechnology companies, supported by proprietary platform technologies and manufacturing facilities located in the UK, France and the United States.

Aptamer Group (LSE:APTA) has initiated a new radiopharmaceutical development programme through a collaboration with Radiopharmium Ltd, aimed at creating a proprietary pipeline of Optimer®-based radioconjugates targeting three high-value therapeutic indications.

The project builds on Aptamer’s existing partnership with a top-three global pharmaceutical company and is expected to expand the company’s radiotherapy portfolio to four development assets. Management is targeting the generation of in vivo data for the programme by the end of 2026.

According to internal research, Optimer® radioligands have demonstrated significantly improved stability compared with leading peptide-based alternatives when labelled with the therapeutic radioisotope Lutetium-177. If validated through further studies, the enhanced stability could extend product shelf life and simplify manufacturing and supply chain logistics for radiopharmaceutical therapies.

The initiative will be led by radiopharmaceutical specialist Dr Louis Allott, whose consultancy Radiopharmium will provide expertise in radiochemistry and access to preclinical testing models. The collaboration is intended to strengthen Aptamer’s efforts to differentiate its Optimer® platform and expand its presence in the rapidly growing market for targeted radiopharmaceutical therapies.

However, the company’s outlook remains constrained by weak financial performance, including a sharp decline in revenue, continued losses, and negative cash flow. Positive technical indicators — including an upward share price trend and supportive momentum — provide some offset, although valuation remains limited by the company’s lack of profitability and the absence of dividend distributions.

More about Aptamer Group plc

Aptamer Group plc is a UK-based life sciences company focused on developing synthetic binding molecules known as Optimer®. These next-generation binders are designed for use in research, diagnostics, and therapeutic applications. The company is increasingly positioning its Optimer® platform for emerging healthcare technologies, particularly in high-growth areas such as radiopharmaceuticals and targeted radioligand therapies.